Rule 2, omit O, gives C5H10
5 – 10/2 + 1 = 1 degree of unsaturation.
Look for 1 pi bond or aliphatic ring.
View original post 107 more words
View original post 107 more words
CAS No.: 865854-05-3
Glycogen Synthase Kinase 3 beta (GSK-3beta; tau Protein Kinase I) Inhibitors
Treatment of Neurologic Drugs (Miscellaneous)
Alzheimer’s Dementia, Treatment ofCerebrovascular Diseases, NP031112; NP-031112, Nypta Zentylor
Tideglusib (NP-12, NP031112) is a potent, selective and irreversible small molecule non-ATP-competitive GSK3 inhibitor that has been investigated as a potential treatment for Alzheimer’s disease and paralysis supranuclear palsy in Phase IIa and IIb clinical trials. The first clinical trial conducted with tideglusib to be published (in English, at least) was phase II and demonstrated that overall tideglusib was well tolerated, except for some moderate, asymptomatic, fully reversible increases in liver enzymes (≥2.5xULN; where ULN=Upper Limit of Normal).
NP-031112 is an inhibitor of glycogen synthase kinase-3 beta (GSK-3beta) in early clinical development for the oral…
View original post 1,271 more words
59467-70-8 CAS NO OF FREE BASE
59467-94-6 MALEATE, Launched – 1982, Roche (Originator)
A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
Midazolam (/mɪˈdæzəlæm/, marketed in English-speaking countries and Mexico under the trade names Dormicum, Hypnovel, andVersed,) is a short-acting drug in the benzodiazepine class developed by Hoffmann-La Roche in the 1970s. The drug is used for treatment of acute seizures, moderate to severe insomnia, and for inducing sedation and amnesia before medical procedures. It possesses profoundly potentanxiolytic, amnestic, hypnotic
View original post 4,549 more words
A non-structural protein 5B polymerase inhibitor
for Treatment of chronic hepatitis C
1. 5H-Imidazo[4,5-c]pyridine, 5-[[6-[2,4-bis(trifluoromethyl)phenyl]-3-pyridazinyl]methyl]-
MOLECULAR FORMULA C25H14F7N5
MOLECULAR WEIGHT 517.4
MANUFACTURER Gilead Sciences, Inc.
CAS REGISTRY NUMBER 1000787-75-6
GS-9190, an RNA-directed RNA polymerase (NS5B) inhibitor, is in phase II clinical evaluation at Gilead for the treatment of hepatitis C virus (HCV) infection. A clinical trial with GS-9190 in combination with peginterferon alfa-2a and ribavirin and with GS-9451 or with GS-9256 in treatment-naive subjects with chronic genotype 1 HCV infection was discontinued due to serious adverse events.
Katholieke Universiteit Leuven (Originator)
View original post 2,055 more words
Danoprevir(ITMN-191) is a peptidomimetic inhibitor of the NS3/4A protease of hepatitis C virus (HCV) with IC50 of 0.2-3.5 nM, inhibition effect for HCV genotypes 1A/1B/4/5/6 is ~10-fold higher than 2B/3A. Phase 2.
Array BioPharma (Originator)
2H-Isoindole-2-carboxylic acid, 4-fluoro-1,3-dihydro-, (2R,6S,12Z,13aS,14aR,16aS)-
Treatment of hepatitis C
MOLECULAR FORMULA C35H46FN5O9S
MOLECULAR WEIGHT 731.8
CODE DESIGNATION R05190591
CAS REGISTRY NUMBER 850876-88-9, 916881-67-9
Danoprevir(ITMN-191) is a peptidomimetic
ITMN-191 (R-7227), a macrocyclic protease inhibitor, is in phase II clinical evaluation for the treatment of chronic hepatitis C virus (HCV) infection as monotherapy and in combination with Pegasys(R) (pegylated interferon alpha-2a) and Copegus(R) (ribavirin). The product candidate is also being evaluated in combination with R-7128 in treatment-naive patients infected with HCV genotype 1.
Danoprevir (ITMN-191; RG-7227), under development by InterMune Inc and Roche Holding AG, is a promising, potent NS3/4A protease inhibitor for…
View original post 2,785 more words
Molecular Formula: C22H24N2O7S Molecular Weight: 460.50016
608141-41-9 CAS NO
CC-10004 (apremilast) is an oral compound that is being studied in multiple Phase III clinical trials for the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases. We successfully completed our early stage studies, demonstrating clinical activity and tolerability and meeting safety endpoints in a placebo controlled proof-of mechanism trial in moderate-to-severe psoriasis and psoriatic arthritis. With the initiation of six multi-center international clinical trials, we are advancing the clinical development of CC-10004.
CC-10004, , Apremilast (USAN), SureCN302992, Apremilast (CC-10004), QCR-202,
View original post 5,021 more words
Glucagon-like peptide 2 (GLP-2) analog; protects small intestinal stem cells from radiation damage.
Gattex (teduglutide) is a recombinant analog of human glucagon-like peptide 2 for the treatment of adults with short bowel syndrome.
[Gly2]hGLP-2, [Gly2]-hGLP-2, ALX-0600,
|Mol. mass||3752.082 g/mol|
Gattex, ALX-0600, (Gly2)GLP-2, Gly(2)-GLP-2, ALX 0600, [Gly2]GLP-2, Glucagon-like peptide II (2-glycine) (human), UNII-7M19191IKG
LAUNCHED 2013, NPS Pharmaceuticals
Company: NPS Pharmaceuticals, Inc.
Date of Approval: December 21, 2012 FDA
POWDER; SUBCUTANEOUS GATTEX
U-1320=TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME WHO ARE DEPENDENT ON PARENTERAL SUPPORT
|Patent No||Patent Expiry Date||Patent use code|
|5789379||Apr 14, 2015||U-1320|
|7056886||Sep 18, 2022||U-1320|
|7847061||Nov 1, 2025||U-1320|
|ORPHAN DRUG EXCLUSIVITY||Dec 21, 2019|
|NEW CHEMICAL ENTITY|
View original post 1,388 more words